Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040816 | 1.00 | GPR119 (0.50) | GPR119PDE10ANR1H2CHRM1GRM1 | |
| SCHEMBL38663441 | 0.89 | GPR119 (0.52) | GPR119PDE10AGRM1 | |
| SCHEMBL10111733 | 0.86 | GPR119 (0.67) | GPR119PDE10ANR1H2 | |
| SCHEMBL15596306 | 0.86 | GPR119 (0.67) | GPR119PDE10ANR1H2 | |
| SCHEMBL27399965 | 0.84 | GPR119 (0.67) | GPR119PDE10ANR1H2 | |
| SCHEMBL20511076 | 0.84 | GPR119 (0.67) | GPR119PDE10ANR1H2 | |
| SCHEMBL652594 | 0.84 | GPR119 (0.71) | GPR119PDE10AGRM1 | |
| SCHEMBL652595 | 0.84 | GPR119 (0.71) | GPR119PDE10AGRM1 | |
| SCHEMBL19078501 | 0.84 | GPR119 (0.50) | GPR119NR1H2 | |
| SCHEMBL22523841 | 0.83 | GPR119 (0.52) | GPR119PDE10ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697888-B2 | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130178458-A1 | SUBSTITUTED (1-(METHYLSULFONYL)AZETIDIN-3-YL)(HETEROCYCLOALKYL)METHANONE ANALOGS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178458-A1 | SUBSTITUTED (1-(METHYLSULFONYL)AZETIDIN-3-YL)(HETEROCYCLOALKYL)METHANONE ANALOGS AS ANTAGONISTS OF MUSCARINIC ACETYLCHOLINE M1 RECEPTORS | CHRM1, CHRM5, CHRM3 | GPR119 285/4885PDE10A 2687/4885NR1H2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.